Will the price of bosutinib/bosutinib be reduced in 2025?

Bosutinib is an oral anticancer drug that targets tyrosine kinases and is mainly used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). Due to its high affinity for ABL kinase and relatively low off-target activity, it has become an important member of the second-generation TKI, especially for patients who are resistant or intolerant to imatinib, dasatinib or nilotinib. With the popularization of the concept of targeted therapy and the improvement of drug accessibility, the scope of application of bosutinib in clinical treatment is gradually expanding. It can not only be used for the back-line treatment of patients with chronic phase CML, but also shows good prospects in the first-line treatment field.

From a global market perspective, the original manufacturer of bosutinib is Pfizer (Pfizer), and the drug has been approved for marketing in the United States, the European Union, Japan and other countries and regions. In China, bosutinib, one of the important drugs for the treatment of CML, has been approved by the Food and Drug Administration in recent years. However, the drug has not yet been included in the national medical insurance list, and the price is still relatively high. Taking the common 100mg tablets as an example, the selling price of overseas original drugs ranges from about 30,000 to 50,000 yuan per box. The specific price is affected by factors such as dosage, supply channels, and exchange rate changes.

Whether prices will be lowered is a common concern for patients and doctors. First of all, if the National Medical Insurance Administration includes the drug in the next round of negotiation catalog, reduces the price through price negotiation and reimburses it, its terminal price will be significantly reduced and the burden on patients will be reduced accordingly. Secondly, as more and more generic drug companies pay attention to this field, in the future, the generic version of bosutinib may be the first to be launched in major generic drug countries such as India and Bangladesh.

Reference materials:https://go.drugbank.com/drugs/DB06616